Literature DB >> 32662255

Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved Renal Function.

Da Hea Seo1, Moonsuk Nam1, Mihye Jung1, Young Ju Suh2, Seong Hee Ahn1, Seongbin Hong1, So Hun Kim1.   

Abstract

BACKGROUND: Recent studies have demonstrated that the levels of adipocyte fatty acid-binding protein (A-FABP) are closely associated with diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM). This study aimed to examine the association between serum A-FABP level and rapid renal function decline in patients with T2DM and preserved renal function.
METHODS: This was a prospective observational study of 452 patients with T2DM and preserved renal function who had serial measurements of estimated glomerular filtration rate (eGFR). Rapid renal function decline was defined as an eGFR decline of >4% per year. The association between baseline serum A-FABP level and rapid renal function decline was investigated.
RESULTS: Over a median follow-up of 7 years, 82 participants (18.1%) experienced rapid renal function decline. Median A-FABP levels were significantly higher in patients with rapid renal function decline, compared to non-decliners (20.2 ng/mL vs. 17.2 ng/mL, P=0.005). A higher baseline level of A-FABP was associated with a greater risk of developing rapid renal function decline, independent of age, sex, duration of diabetes, body mass index, systolic blood pressure, history of cardiovascular disease, baseline eGFR, urine albumin creatinine ratio, total cholesterol, glycosylated hemoglobin, high-sensitivity C-reactive protein and use of thiazolidinedione, insulin, angiotensin-converting-enzyme inhibitors and angiotensin II-receptor blockers and statin (odds ratio, 3.10; 95% confidence interval, 1.53 to 6.29; P=0.002).
CONCLUSION: A high level of serum A-FABP is associated with an increased risk of rapid renal function decline in patients with T2DM and preserved renal function. This suggests that A-FABP could play a role in the progression of DKD in the early stages.

Entities:  

Keywords:  Diabetes mellitus, type 2; Diabetic nephropathies; FABP4 protein, human

Year:  2020        PMID: 32662255     DOI: 10.4093/dmj.2019.0221

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


  3 in total

1.  The role of statins in patients with early diabetic nephropathy: A protocol for systematic review and meta-analysis.

Authors:  Xi Zhao; Shu Chun Zhou; Xiu Fang Wang; Hong Wu Liao
Journal:  Medicine (Baltimore)       Date:  2022-06-17       Impact factor: 1.817

2.  Serum Adipocyte Fatty-Acid Binding Protein as an Independent Marker of Peripheral Artery Disease in Patients with Type-2 Diabetes Mellitus.

Authors:  Bang-Gee Hsu; Chin-Yee Mah; Du-An Wu; Ming-Chun Chen
Journal:  Int J Environ Res Public Health       Date:  2022-08-02       Impact factor: 4.614

3.  Serum fatty acid-binding protein 4 levels and responses of pancreatic islet β-cells and α-cells in patients with type 2 diabetes.

Authors:  Hong Wang; Jie Cao; Jian-Bin Su; Xue-Qin Wang; Xing Wang; Dong-Mei Zhang; Xiao-Hua Wang
Journal:  Diabetol Metab Syndr       Date:  2021-06-26       Impact factor: 3.320

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.